NANOSONICS LIMITED (NAN)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

NAN

NAN - NANOSONICS LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 0.98
Index: ASX300 | ALL-ORDS

Nanosonics is an Australian medical device company manufacturing high level disinfection systems to reduce the spread of infection. Founded in 2001, the company listed on the ASX in 2007.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$2.67

27 Aug
2026

-0.160

OPEN

$2.83

-5.65%

HIGH

$2.86

2,688,198

LOW

$2.65

TARGET
$3.35 25.5% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AVE . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CTE . CU6 . CVB . CYC . EBR . EIQ . EMV . EYE . FPH . IME . IMR . IPD . LDX . MX1 . ONE . PCK . PEB . PGC . PME . RAP . RMD . SHG . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
NAN: 1
Title FY25
Actual		 FY26
Actual		 FY27
Forecast		 FY28
Forecast
EPS (cps) xxx 5.9 3.9 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx - 13.5% - 34.7% xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 70.9 xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202120222023202420252026
EPS Basic xxxxxxxxxxxxxxx5.9
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx203.5 M
Book Value Per Share xxxxxxxxxxxxxxx72.8
Net Operating Cash Flow xxxxxxxxxxxxxxx22.6 M
Net Profit Margin xxxxxxxxxxxxxxx8.77 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202120222023202420252026
Return on Capital Employed xxxxxxxxxxxxxxx8.35 %
Return on Invested Capital xxxxxxxxxxxxxxx7.89 %
Return on Assets xxxxxxxxxxxxxxx6.08 %
Return on Equity xxxxxxxxxxxxxxx8.35 %
Return on Total Capital xxxxxxxxxxxxxxx6.54 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx17.4 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202120222023202420252026
Short-Term Debt xxxxxxxxxxxxxxx3 M
Long Term Debt xxxxxxxxxxxxxxx20 M
Total Debt xxxxxxxxxxxxxxx23 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx155 M
Price To Book Value xxxxxxxxxxxxxxx4.58

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202120222023202420252026
Capex xxxxxxxxxxxxxxx5.1 M
Capex % of Sales xxxxxxxxxxxxxxx2.52 %
Cost of Goods Sold xxxxxxxxxxxxxxx55 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx134 M
Research & Development xxxxxxxxxxxxxxx29 M
Investments - Total xxxxxxxxxxxxxxx1 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.3

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

xx/xx/xxxx

2

xxxxxxxxx xx xxxxxxxxxx xxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

26/08/2026

3

Hold

$3.20

19.85%

Bell Potter maintains its Hold recommendation for Nanosonics with its target price decreased to $3.20 from $3.60 following an FY26 financial result featuring revenues of $203.7m, up 3% year-on-year, which missed market consensus.

Operational performance was constrained by a slowdown in Trophon revenue growth in the United States, alongside headwinds from adverse weather, tariffs, shipping costs, and currency movements that impacted reported revenue by -$7.0m and EBIT by -$5.6m.

FY27 earnings are downgraded significantly due to higher operating expenses as the company invests in additional US headcount ahead of the upcoming Coris launch.

The analyst highlights that Trophon growth has matured, hence the long-term investment thesis is now contingent on the successful commercialisation of the Coris endoscope reprocessing system.

FORECAST
Bell Potter forecasts a full year FY27 dividend of 0.00 cents and EPS of 4.20 cents.
Bell Potter forecasts a full year FY28 dividend of 0.00 cents and EPS of 3.70 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

04/03/2026

1

Buy

$5.55

107.87%

Nanosonics' 1H26 missed on revenue but it was nothing dramatic, in Canaccord Genuity's view. Earnings were ahead, FY26 guidance is maintained and CORIS is launching (controlled market release underway).

At current share price, the Trophon-only business appears to be trading at a -15% discount to international med-tech peers. Canaccord can see how CORIS can make Nanosonics seem optically expensive, until it too becomes earnings-generative.

Target rises to $5.55 from $5.43, Buy retained.

FORECAST
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of 6.00 cents.
Access Extra Coverage Research History >

NAN STOCK CHART

FNArena News on NAN

1
FNArena Corporate Results Monitor – 26-08-2026

Aug 26 2026 - Australia
2
Treasure Chest: Beware Aussie Healthcare

Jul 17 2026 - Treasure Chest
3
Rudi’s View: AI Is Making A Come-Back

May 13 2026 - Rudi's View
4
Rudi’s View: Best Buys & Conviction Calls

Apr 23 2026 - Rudi's View
5
The Biotech ‘Industrialisation’

Apr 20 2026 - Small Caps

Latest Medical Equipment & Devices News

1
Rudi Interviewed: Bear Market Be Gone

Aug 13 2026 - Rudi's View
2
Are Headwinds Building For ResMed In FY27?

Jul 14 2026 - Australia
3
A Technical Breakout For ResMed

Jul 07 2026 - Technicals
4
Awaiting Catapult Sports’ Fundamental Re-Rating

Jun 15 2026 - Small Caps
5
Treasure Chest: Pro Medicus

Jun 04 2026 - Treasure Chest
6
Cochlear’s Shock Downgrade Raises Concerns

Apr 23 2026 - Australia
7
GLP-1s Drive Strong Quarter For ResMed

Feb 02 2026 - Australia
8
ImpediMed Ready To Scale Up

Dec 16 2025 - Small Caps
9
Fisher & Paykel Healthcare’s Superior Profile

Dec 02 2025 - Australia
10
4DMedical Poised For A Recovery

Nov 25 2025 - Technicals